6 14 102
www.wsj.com
Exclusive | Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%
The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.
Bluesky · Hashtag
#$NVO
22
posts · 30d
14
users
1
posts / day
1.6
posts / user
+ 67% vs last week
#$NVO is an active hashtag on Bluesky. In the last 30 days, 14 people shared 22 posts with it — around 1 a day. Activity is up 67% versus the previous week, peaking on Sep 21 with 5 posts.
#$NVO posts per day (last 30 days)
Posts with #$NVO
Belt sizes down, wallet heft up.
$NVO cutting Ozempic, WeGovy listing prices as much as 50%.
5 12 69
$HIMS launching $49 WeGovy knock-off. $NVO -8% pre-market, if it closes here would be the lowest in almost 5 years.
www.reuters.com/business/….
1 3 32
Doing my thing.
Couple big decisions today.
$NVO out. (growing competition, fewer ways to defend moat, getting worse, took f loss)
$TDG out. High qlty, highly levered play needing falling rates. Bad entry getting worse.
Trimmed $UNH to 9.5%(win)
Added to $IBKR
+51.5% <13 mo., 6 co’s, 20% cash
4 0 12
…added more #$NVO today
I just ran across Torghatten Capital’s (Arne) write-up on Novo Nordisk. Followed him for years; solid thought process. Already built a solid position, so is this confirmation bias? Maybe—but solid points were made.
#LongtermHold
open.substack.com/pub/tor….
open.substack.com
Novo Nordisk – A Victim of Its Own Hype
Background
3 1 12
#$NVO
“someone lost their job”
I feel this will be resolved. Does this explain the price action today? There was a downgrade as well. Feels like noise, imho.
2 1 11
📰 $NVO News TLDR
Novo Nordisk stock dropped ~7-8% after its 2030 post-Wegovy growth strategy disappointed investors, targeting 5+ new blockbusters but failing to ease competition fears. The company is diversifying into hair loss and expanding a UNICEF partnership covering 80M+ children.
0 0 0
$NVO is starting to look more interesting, but the story is changing.
The question is no longer just whether Wegovy can keep growing.
It’s increasingly about whether Novo Nordisk can build the next obesity growth engine after Wegovy.
static.klipy.com
Jonah Hill Screaming Reaction
ALT: Jonah Hill Screaming Reaction
1 0 0
09 21 26 Notable Stocks In Play according to Unusual Options Flow
www.patreon.com/posts/170….
$PFE
$NVO
$CMCSA
$CNQ
$TSM
$JBLU
www.patreon.com
💎 09/21/26 Live Data💎Latest Live Unusual Options Database Available💎Contains The Top 400+ Most Unusual Live Trades💎Trade Details Inside Report | THE OPTIONS BULLY
***** 💎 Here Are The Top 28 Unusual Options Trade Stocks So Far but 400+ Unusual Trades available in the Full Report (See attachment For Tr
0 0 0
Novo looking for fresh shot at redemption with new CagriSema data $NVO firstwordpharma.com/story…
0 0 0
$NVO: Novo Nordisk's Phase 3 trials show CagriSema superior weight loss and non-inferior HbA1c reduction versus tirzepatide.
0 0 0
$NVO shares fell as much as 5% on 21 Sept 2026 after its capital markets day. Distant 2030 goals failed to ease concerns over patents and $LLY. notreload.xyz/xy/novo-shar...
notreload.xyz
Novo Shares Slide as Long-Term Goals Disappoint Market
Distant 2030 goals failed to ease concerns over patents and Lilly.
0 0 0
🟢 $NVO — Regulatory Designation
CHMP Positive Opinion - FREHEMGO (denecimig) Recommended for EU Approval in Haemophilia A
On September 17, 2026, the CHMP of the EMA adopted a positive opinion recommending marketing authorisation for FREHEMGO (denecimig) to trea…
biostock.app/symbols/NVO
0 0 0
CHMP backs FREHEMGO for haemophilia A in children and adults. $NVO also partners with Orbis on oral cardiometabolic medicines worth up to $1.4B. notreload.xyz/xy/novo-eu-n...
notreload.xyz
Novo: EU nod for FREHEMGO + $1.4bn oral-drug deal
CHMP recommends FREHEMGO (denecimig) for haemophilia A, with or without inhibitors. Novo and Orbis will develop oral cardiometabolic drugs.
0 0 0
Novo puts Anthropic's Claude to work on drug R&D challenges $NVO firstwordpharma.com/story…
0 0 0
$NVO $LLY
What aboot $ALT ?
Well, Novo just pulled out of Ascendis. Means, they will be looking elsewhere. Altimmune offers a competitive edge with Lilly, especially the ALD and AUD indications
Then, the hidden Oral option
Of course, $VKTX is on radars too
substack.com/@bambiopicks...
substack.com
BAM! (@bambiopicks)
$NVO walks away from Ascendis That opens doors for $VKTX Oral Obesity If the upcoming $VKTX data is strong, $NVO may take out Viking. Novo has not deployed any meaningful capital this year. Eve...
0 0 0
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.